Taysha Gene Therapies Business Summary

Taysha Gene Therapies, Inc. (TSHA) is a clinical-stage biotechnology company that generates revenue primarily through strategic licensing agreements and R&D collaborations, most notably its partnership with Astellas Pharma, although it regained full global rights to its lead program, TSHA-102, in late 2025. The company’s primary business segments are focused on the discovery and development of adeno-associated virus (AAV)-based gene therapies for monogenic central nervous system (CNS) disorders. Its flagship clinical program, TSHA-102, utilizes a novel miRNA-responsive auto-regulatory element (miRARE) to treat Rett syndrome and is currently in the pivotal REVEAL Phase 3 trial. Within the competitive landscape, Taysha contends with Neurogene (NGN-401), Acadia Pharmaceuticals (Daybue), and Ovid Therapeutics; Taysha distinguishes itself as a frontrunner in the gene therapy space by targeting the genetic root cause of Rett syndrome with a self-regulating delivery mechanism designed to prevent protein overexpression toxicity. Taysha was founded by RA Session II, alongside scientific founders Dr. Steven Gray and Dr. Berge Minassian, both of whom are pioneers from the UT Southwestern Gene Therapy Program. The current leadership team is led by CEO and Chairman Sean P. Nolan, the former CEO of AveXis (acquired by Novartis for $8.7 billion), and President and Head of R&D Dr. Sukumar Nagendran, who also held senior leadership roles at AveXis. Other key executives include CFO Kamran Alam and Frederick Porter, who serves as Chief of Staff and Technical Operations Officer. The company is backed by a high-pedigree investor base including RA Capital Management, RTW Investments, and Avoro Capital Advisors, with Astellas Pharma maintaining a significant strategic interest despite the recent rights reversion.